Molecular Profile Detail

Profile Name STAG2 dec exp
Gene Variant Detail

STAG2 dec exp (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
STAG2 S653* glioblastoma multiforme sensitive Olaparib Preclinical - Cell culture Actionable In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817). 21852505 24356817
STAG2 S653* glioblastoma multiforme sensitive Camptothecin Preclinical - Cell culture Actionable In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 S653*, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817). 24356817 21852505
STAG2 mutant myelodysplastic syndrome not applicable N/A Guideline Prognostic STAG2 mutations are associated with a poor prognosis in patients with myelodysplastic syndrome (NCCN.org). detail...
STAG2 dec exp colorectal cancer sensitive Olaparib Preclinical Actionable In a preclinical study, colorectal cancer cells with knockdown of STAG2 expression demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture (PMID: 24356817). 24356817
NRAS mut STAG2 dec exp melanoma decreased response Trametinib Preclinical - Cell culture Actionable In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in NRAS mutated melanoma cell lines resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726). 27500726
BRAF mut STAG2 dec exp melanoma decreased response Trametinib Preclinical - Cell culture Actionable In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) in culture (PMID: 27500726). 27500726
BRAF mut STAG2 dec exp melanoma decreased response Dabrafenib Preclinical - Cell culture Actionable In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Tafinlar (dabrafenib) in culture (PMID: 27500726). 27500726
BRAF mut STAG2 dec exp melanoma decreased response Vemurafenib Preclinical - Cell line xenograft Actionable In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cell lines resulted in decreased response to Zelboraf (vemurafenib) both in culture and in cell line xenograft models (PMID: 27500726). 27500726
BRAF mut STAG2 dec exp melanoma decreased response Dabrafenib + Trametinib Preclinical - Cell culture Actionable In a preclinical study, decreasing Stag2 expression level through shRNA knockdown in BRAF mutated melanoma cells resulted in decreased response to Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment in culture (PMID: 27500726). 27500726
STAG2 N357fs glioblastoma multiforme sensitive Olaparib + Temozolomide Preclinical - Cell culture Actionable In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and Temodar (temozolomide) compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817). 21852505 24356817
STAG2 N357fs glioblastoma multiforme sensitive Olaparib Preclinical - Cell culture Actionable In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Lynparza (olaparib) in culture, resulting in decreased proliferation and colony formation, and increased DNA damage compared to isogenic cells with wild-type STAG2 (PMID: 24356817). 21852505 24356817
STAG2 N357fs glioblastoma multiforme sensitive Rucaparib Preclinical - Cell culture Actionable In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505), demonstrated increased sensitivity to treatment with Rubraca (rucaparib) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817). 21852505 24356817
STAG2 N357fs glioblastoma multiforme sensitive Veliparib Preclinical - Cell culture Actionable In a preclinical study, a glioblastoma cell line harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to treatment with Veliparib (ABT-888) in culture compared to isogenic cells with wild-type STAG2 (PMID: 24356817). 21852505 24356817
STAG2 N357fs glioblastoma multiforme sensitive Camptothecin + Olaparib Preclinical - Cell culture Actionable In a preclinical study, glioblastoma cells harboring a STAG2 mutation (reported as STAG2 N357fs, PMID: 21852505) demonstrated increased sensitivity to the combination of Lynparza (olaparib) and camptothecin compared to isogenic cells with wild-type STAG2 in culture (PMID: 24356817). 21852505 24356817
Clinical Trial Phase Therapies Title Recruitment Status